Targeting downstream of EGFR by using Trametinib, a mitogen activated protein kinase kinase (MEK) inhibitor, in MDA-MB-231 breast cancer and MDA-MB-435 melanoma cells causes them to stiffen [88]. Here, EGFR is linked to breast carcinoma.